Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

STADA 2011 Prelim. Net Profit Falls; Backs Long-term Targets - Quick Facts

STADA Arzneimittel AG (STDAF.PK,STDAY.PK) confirmed its 2011 preliminary results, by reported a plunge in its 2011 net income to 22.0 million euros or 0.37 euros per share from 68.4 million euros or 1.16 euros per share a year ago. However, on an adjusted basis, net profit totaled 146.6 million euros or 2.49 euros per share, higher than last year's 133.3 million euros or 2.27 euros per share.

With varying development in individual national markets, Group sales went up 5% in the reporting year to 1.71 billion euros from 1.63 billion euros in the earlier year period. When effects on sales based on changes in the Group portfolio and currency effects are taken into account, Group sales rose 5% in 2011.

The company said that 2011 reported key earnings figures dropped significantly due to high burdening one-time special effects, mainly as a result of impairments on receivables from various Serbian pharmaceutical wholesalers, operationally, i.e. excluding one-time special effects, however, they all exceeded the key earnings figures, adjusted accordingly, of the prior year.

Despite these earnings burdening one-time special effects from the further implementation of the "STADA - build the future" program, the Executive Board expects a very significant increase in reported net income for 2012 as compared with 2011.

In addition, the Executive Board confirmed its long-term prognosis envisaged for 2014, according to which Group sales of nearly 2.15 billion euros, at an adjusted level, EBITDA of about 430 million euros and net income of around 215 million euros should be reached.

Register
To receive FREE breaking news email alerts for Stada Arzneimittel AG and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
There are just two days to go for the big event of India making its maiden foray to Mars. The nation's first interplanetary probe known as Mars Orbiter Mission (MOM) spacecraft is scheduled to enter the Martian orbit at 7.30 AM IST on September 24, 2014. A US satellite to study Mars' upper atmosphere has entered the Red Planet's orbit. NASA said its Mars Atmosphere and Volatile Evolution (MAVEN) spacecraft successfully entered the orbit at 10:24 p.m. EDT Sunday, completing a 10-month interplanetary journey of 442 million miles, or 711 million kilometers. MAVEN is the first spacecraft dedicated to exploring the tenuous higher atmosphere of Mars. Bundesbank President Jens Weidmann has criticized the European Central Bank's latest measures to boost the euro area economy, such as the planned purchases of covered bonds and asset-backed securities and covered bonds, as well as the interest rate reduction this month. The latest decisions suggest...
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.